Jessica Tsui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jessica Tsui has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Brian Aguirre
Department of Pathology Lab Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA 90095, USA
31 shared publications - Madhuri Wadehra
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095, USA
31 shared publications - Ann M. Chan
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
30 shared publications - Anna M. Wu
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
30 shared publications - Felix B. Salazar
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
30 shared publications - Jason Thanh Lee
Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California
30 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by American Society for Clinical Investigation in JCI Insight
STING agonism orchestrates myeloid-predominant tumor necrosis preceding T cell-dependent regression in osteosarcoma
An immunosuppressive, macrophage-rich tumor microenvironment (TME) is a barrier to immunotherapy across many cancers including osteosarcoma, where immunotherapy has largely failed. cGAS-STING agonism has been explored to inflame such tumors, yet the mechanisms of STING-mediated TME remodeling remain poorly understood, especially in sarcomas. Using multi-modal single cell analysis, we show that systemic STING agonism in osteosarcoma triggers a myeloid-predominant inflammatory response and rapid tumor necrosis, followed by a T cell-mediated response, immunologic memory, and long-term cure in some models. Within two hours of treatment, STING agonism induces pro-inflammatory interferon programs in tumor-associated macrophages and monocytes, with additional contributions from endothelial cells. Efficacy persists in the absence of tumor-intrinsic STING or IFNAR, confirming that the therapeutic axis resides within the host TME rather than the tumor cell compartment. While cGAS-STING is frequently repressed in human osteosarcoma models of aggressive disease, a STING activation gene signature predicts survival in newly diagnosed patients, suggesting that this pathway is engaged during tumor progression. Together, these data identify an opportunity to exploit the myeloid compartment of osteosarcoma with STING pathway therapies, charting a path forward for engaging the TME to secure long term cure in an aggressive malignancy still treated with highly toxic chemotherapy.
- 22 October 2026
- Published by American Society for Clinical Investigation in JCI Insight
Open AccessSTING agonism orchestrates myeloid-predominant tumor necrosis preceding T cell-dependent regression in osteosarcoma
An immunosuppressive, macrophage-rich tumor microenvironment (TME) is a barrier to immunotherapy across many cancers including osteosarcoma, where immunotherapy has largely failed. cGAS-STING agonism has been explored to inflame such tumors, yet the mechanisms of STING-mediated TME remodeling remain poorly understood, especially in sarcomas. Using multi-modal single cell analysis, we show that systemic STING agonism in osteosarcoma triggers a myeloid-predominant inflammatory response and rapid tumor necrosis, followed by a T cell-mediated response, immunologic memory, and long-term cure in some models. Within two hours of treatment, STING agonism induces pro-inflammatory interferon programs in tumor-associated macrophages and monocytes, with additional contributions from endothelial cells. Efficacy persists in the absence of tumor-intrinsic STING or IFNAR, confirming that the therapeutic axis resides within the host TME rather than the tumor cell compartment. While cGAS-STING is frequently repressed in human osteosarcoma models of aggressive disease, a STING activation gene signature predicts survival in newly diagnosed patients, suggesting that this pathway is engaged during tumor progression. Together, these data identify an opportunity to exploit the myeloid compartment of osteosarcoma with STING pathway therapies, charting a path forward for engaging the TME to secure long term cure in an aggressive malignancy still treated with highly toxic chemotherapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S3. EMP2 expression in cancer cell lines. A. Based on public repositories, upregulation of EMP2 occurs in breast, brain, and ovarian cancers, while downregulation is predicted in hematopoietic cancers. B, C. Flow cytometry studies using a panel of human (B) and murine (C) cancer cell lines to validate differential EMP2 expression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S3. EMP2 expression in cancer cell lines. A. Based on public repositories, upregulation of EMP2 occurs in breast, brain, and ovarian cancers, while downregulation is predicted in hematopoietic cancers. B, C. Flow cytometry studies using a panel of human (B) and murine (C) cancer cell lines to validate differential EMP2 expression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S2. EMP2 expression in the mouse. Expression of EMP2 was determined by immunohistochemical staining in C57B/6 WT or EMP2 knockout mice with representative images shown from select tissue. Magnification: 400X.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S2. EMP2 expression in the mouse. Expression of EMP2 was determined by immunohistochemical staining in C57B/6 WT or EMP2 knockout mice with representative images shown from select tissue. Magnification: 400X.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Tables from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S5. Binding characteristics. Analysis of the various anti-EMP2−DFO conjugates using flow cytometry binding on U87MG/EMP2FLuc. N=3, with the EC50 determined using nonlinear regression. B. 10:1 DFO:mAb ratio retains specific binding to EMP2 high (4T1FLuc, CT26) murine cell lines compared to low cells (Panc02). N=3, with a representative experiment shown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S5. Binding characteristics. Analysis of the various anti-EMP2−DFO conjugates using flow cytometry binding on U87MG/EMP2FLuc. N=3, with the EC50 determined using nonlinear regression. B. 10:1 DFO:mAb ratio retains specific binding to EMP2 high (4T1FLuc, CT26) murine cell lines compared to low cells (Panc02). N=3, with a representative experiment shown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S4. DFO-conjugated anti-EMP2 mAb characteristics. A. Analysis of the various anti-EMP2−DFO conjugates using polyacrylamide gel electrophoresis (PAGE) showing changes in the migration of the intact antibody. B. Analysis of the various anti-EMP2−DFO conjugates to the EMP2 peptide or a non-specific peptide by ELISA. C. Predicted number of chelators per mAb based on MALDI-TOF analysis. Changes in the molecular weight of the native antibody (~150kD) are attributed to modification with the various molar equivalents of DFO.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S4. DFO-conjugated anti-EMP2 mAb characteristics. A. Analysis of the various anti-EMP2−DFO conjugates using polyacrylamide gel electrophoresis (PAGE) showing changes in the migration of the intact antibody. B. Analysis of the various anti-EMP2−DFO conjugates to the EMP2 peptide or a non-specific peptide by ELISA. C. Predicted number of chelators per mAb based on MALDI-TOF analysis. Changes in the molecular weight of the native antibody (~150kD) are attributed to modification with the various molar equivalents of DFO.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S7. ImmunoPET imaging with 89Zr-DFO- anti-EMP2 mAb of U87MG/EMP2Fluc or sham injected nude mouse in an intracranial model. All mice received the same surgical procedures, but they were injected with either U87MG/EMP2Fluc cells or saline (sham treated). A. Bioluminescence imaging showing the presence of intracranial U87MG/EMP2Fluc cells or no cells in the sham in a representative set of animals. B. Maximum intensity projection (MIP) images were acquired at 24 and 120 hours post-intravenous injection of 89Zr-DFO-anti-EMP2 mAb in a representative animal injected with U87/EMP2Fluc vs sham treated animal. C. In vivo biodistribution of sham mice at 120 hrs indicate that there was no measurable uptake of 89Zr-DFO-anti-EMP2 mAb in the brain. N=2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S7. ImmunoPET imaging with 89Zr-DFO- anti-EMP2 mAb of U87MG/EMP2Fluc or sham injected nude mouse in an intracranial model. All mice received the same surgical procedures, but they were injected with either U87MG/EMP2Fluc cells or saline (sham treated). A. Bioluminescence imaging showing the presence of intracranial U87MG/EMP2Fluc cells or no cells in the sham in a representative set of animals. B. Maximum intensity projection (MIP) images were acquired at 24 and 120 hours post-intravenous injection of 89Zr-DFO-anti-EMP2 mAb in a representative animal injected with U87/EMP2Fluc vs sham treated animal. C. In vivo biodistribution of sham mice at 120 hrs indicate that there was no measurable uptake of 89Zr-DFO-anti-EMP2 mAb in the brain. N=2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S6. Pharmacokinetics and in vivo tumor expression. A. Tumor growth of syngeneic 4T1FLuc, CT26, and Panc02 tumors over the imaging period. B. Correlation of the average EMP2 histological score and mean %ID/cc in 4T1FLuc, CT26 and Panc02 tumors. C. Representative staining of EMP2 in 4T1FLuc, CT26 and Panc02 tumors. Magnification: 100m. D. Pharmacokinetics of the anti-EMP2 mAb as measured by western blot detection of the anti-Fc portion of the mAb. Mice were injected with 200 g or 20 g of the anti-EMP2 mAb. Cmax was defined by quantitation at t=2 hrs with the PK estimated at 140 hrs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S6. Pharmacokinetics and in vivo tumor expression. A. Tumor growth of syngeneic 4T1FLuc, CT26, and Panc02 tumors over the imaging period. B. Correlation of the average EMP2 histological score and mean %ID/cc in 4T1FLuc, CT26 and Panc02 tumors. C. Representative staining of EMP2 in 4T1FLuc, CT26 and Panc02 tumors. Magnification: 100m. D. Pharmacokinetics of the anti-EMP2 mAb as measured by western blot detection of the anti-Fc portion of the mAb. Mice were injected with 200 g or 20 g of the anti-EMP2 mAb. Cmax was defined by quantitation at t=2 hrs with the PK estimated at 140 hrs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S1. Summary of human EMP2 expression. A. HPA-RNAseq data depicting EMP2 mRNA expression in normal tissues. The image is reproduced from (https:www.ncbi.nlm.nih.gov/gene/2013). B. Immunohistochemical staining of representative human tissues using anti-EMP2 antisera. Magnification: 400X.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from 89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
S1. Summary of human EMP2 expression. A. HPA-RNAseq data depicting EMP2 mRNA expression in normal tissues. The image is reproduced from (https:www.ncbi.nlm.nih.gov/gene/2013). B. Immunohistochemical staining of representative human tissues using anti-EMP2 antisera. Magnification: 400X.